Feeds:
Posts
Comments

Posts Tagged ‘Biogen’

This will be the final Impactiviti Daily for 2009. We’ll pick up again in the new year. Have a delightful holiday season!

TODAY’S NEWS

Deals – J&J and Merck get hits, Biogen strikes out.

From PharmaExec – a new commercialization model needed for pharma? – The days when biopharmaceutical companies could rely upon a steady stream of blockbuster products to fuel sales and support large, fixed-cost infrastructures appear to be over. It is clear that with the issues facing the pharmaceutical industry — coupled with a changing future environment — the current commercial model is too cumbersome to deal with hard economic conditions or to react to new stakeholder environmentsmore

Pfizer and BI get expanded label for Spiriva for COPD – Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). SPIRIVA HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with COPD, which includes chronic bronchitis, emphysema, or bothmore

Cancer genomes revealed – this is pretty cool, actually. A big step toward personalized medicine.

Medical Rep certification – coming soon!

RECOMMENDED

Training and eMarketing. The Impactiviti network has great suppliers for all your training, social media, and eMarketing needs.  We “matchmake” best-in-class vendor/providers with clients’ needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

JUST FOR FUN

Business Week gives their visual and descriptive accounting of the 50 ugliest cars of the last 50 years. There are some…umm…beauties in there.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Study ended early – who’s the winner? Zetia or Niaspan?

Could New Jersey lose its pharma edge?

BiogenIdec gets a fast track – Biogen Idec Inc., a Cambridge company known for its multiple sclerosis drugs, said that US Food and Drug Administration has granted it Fast Track designation for a potential treatment of relapsing multiple sclerosis…more

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

J&J cutting 900 positions, mostly in salesDiversified healthcare company Johnson & Johnson said on Thursday it was eliminating 900 positions from its Ortho-McNeil-Janssen Pharmaceutical unit in the latest downsizing move in the drug industry. The reductions occurred across Ortho-McNeil-Janssen, but the majority of the jobs impacted were from sales, spokeswoman Kara Russell said.

More big-name hospital systems limiting drug industry tiesJust a few days after Johns Hopkins announced a stricter conflict-of-interest policy for its doctors, some big-name Massachusetts hospitals are moving in a similar direction. Doctors at Partners HealthCare, a system that includes Harvard-affiliated Mass General and Brigham and Women’s hospitals as well as outpatient clinics, will be barred from accepting free meals from drug makers. They will also be prohibited from serving on drug-company “speakers’ bureaus,” where doctors are paid to give talks to other doctors.

BMS, Biogen CEOs – no rush to be acquired, thank you very much.

PLUS – Priming the Discussion: your input sought on an upcoming session on Pharma Social Media and Business Opportunities.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Just got back from the ePharma Summit in Philadelphia and it’s going to take a couple days to digest, catch up, write up, etc. But here are a few news items for your Thursday:

Two more pharma companies jump aboard YouTube with their own channels – this is a promising direction for companies getting their toes in the water with social media applications.

Promising Phase III data on Zometa’s efficacy in breast cancer reductionA newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa® (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone.

Atacand and kidney failure prevention? Very interesting. And, will Sanofi’s Multaq make it to market this time?

Rumor mill – Sanofi and Biogen?

For the Record – a quick muse on how I really feel about the pharma industry…

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

.

Reblog this post [with Zemanta]

Read Full Post »

Wyeth gets Pristiq approved (a derivative of Effexor) for Major Depressive Disorder.

Speaking of anti-depressants, lots of noise being made – and arguments back and forth – about whether they are effective at all.

Eisai gets an additional approval for anti-nausea drug Aloxi, and a priority review for Aciphex (GERD) in patients aged 12-16

Very encouraging results for Novartis‘ new kidney cancer drug Everolimus – late-stage testing was stopped early because of significant survival benefits in patients.

Centocor launches a blog (more pharmas should). Here’s the what and why.

Biogen‘s Tysabri linked to liver damage.

More bad news for EPOs. Links to blood clots and death.

The Schering/Organon merger produces the expected job cuts.

Why did drug costs slow down in 2007? A bumper crop of generics.

Pharma still taking baby steps on the web, according to article on Pharma Exec website.

Read Full Post »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers